About this event:

Date: November 7, 2023

Time: 11 am ET | 8 am PT |
5 pm CEST

Duration: 30 minutes

To determine the safety of biologics, the potential of the manufacturing process to inactivate and/or remove potential viral contaminants is addressed. Therefore, starting material is typically spiked with a single virus solution and then subjected to the removal/inactivation procedure.

For significantly saving resources such as material, time, and manpower, a co-virus spike approach using Murine Leukemia Virus (MuLV) and Minute Virus of Mice (MVM) was tested for its applicability in viral clearance studies.

In this webinar, Charles River will address:

• The possibility to determine the virus specific clearance capacity of a manufacturing step even under co-spike conditions by quantifying each virus separately.
• The comparison of log₁₀ reduction factors obtained by chromatography and virus retentive filtration using single virus spike versus co-virus spike approach.
• The benefits in terms of saving time and resources when applying the MuLV-MVM co-spike in your viral clearance study:
  
  
  • Up to 50% savings in chromatography columns, virus retentive filters, and process intermediates.
  • Up to 50% time reduction for viral spiking runs.
  • Up to 45% cost savings in process performance costs when CRL performs the process.